ELOX Eloxx Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ELOX

Price (delayed)

$6.97

Market cap

$15.1M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$14.33

Enterprise value

$28.71M

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates (designed to be eukaryotic ribosomal selective glycosides) that are formulated to treat rare and ultra-rare premature stop ...

Highlights
The EPS has soared by 60% YoY and by 14% QoQ
ELOX's net income has surged by 56% year-on-year and by 15% since the previous quarter
The company's quick ratio has shrunk by 87% YoY and by 68% QoQ
Eloxx Pharmaceuticals's equity has plunged by 53% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.eloxxpharma.com
Peers: OVID

Key stats

What are the main financial stats of ELOX
Market
Shares outstanding
2.17M
Market cap
$15.1M
Enterprise value
$28.71M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$30.68M
EBITDA
-$29.99M
Free cash flow
-$29.21M
Per share
EPS
-$14.33
Free cash flow per share
-$13.48
Book value per share
-$7.52
Revenue per share
$0
TBVPS
$3.32
Balance sheet
Total assets
$7.2M
Total liabilities
$23.49M
Debt
$18.77M
Equity
-$16.29M
Working capital
-$13.06M
Liquidity
Debt to equity
-1.15
Current ratio
0.33
Quick ratio
0.27
Net debt/EBITDA
-0.45
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-139.2%
Return on equity
N/A
Return on invested capital
-641.5%
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ELOX stock price

How has the Eloxx Pharmaceuticals stock price performed over time
Intraday
-0.43%
1 week
-3.6%
1 month
12.06%
1 year
-43.79%
YTD
282.97%
QTD
177.69%

Financial performance

How have Eloxx Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.95M
Net income
-$30.68M
Gross margin
N/A
Net margin
N/A
Eloxx Pharmaceuticals's operating income has soared by 58% YoY and by 16% from the previous quarter
ELOX's net income has surged by 56% year-on-year and by 15% since the previous quarter

Growth

What is Eloxx Pharmaceuticals's growth rate over time

Valuation

What is Eloxx Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has soared by 60% YoY and by 14% QoQ
Eloxx Pharmaceuticals's equity has plunged by 53% from the previous quarter

Efficiency

How efficient is Eloxx Pharmaceuticals business performance
The company's return on invested capital rose by 27% YoY but it fell by 17% QoQ
The ROA is down by 20% since the previous quarter and by 2.3% year-on-year

Dividends

What is ELOX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELOX.

Financial health

How did Eloxx Pharmaceuticals financials performed over time
The total assets is 69% smaller than the total liabilities
The company's quick ratio has shrunk by 87% YoY and by 68% QoQ
The current ratio has dropped by 85% year-on-year and by 62% since the previous quarter
ELOX's debt to equity has dropped by 156% year-on-year but it has surged by 53% since the previous quarter
Eloxx Pharmaceuticals's equity has plunged by 53% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.